NASDAQ:IDRA - Idera Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.06 +0.16 (+5.52 %)
(As of 01/16/2019 04:00 PM ET)
Previous Close$2.90
Today's Range$2.90 - $3.18
52-Week Range$2.65 - $20.40
Volume300,800 shs
Average Volume322,573 shs
Market Capitalization$83.18 million
P/E Ratio-0.91
Dividend YieldN/A
Beta2.88
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Exton, Pennsylvania.

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IDRA
CUSIPN/A
Phone484-348-1600

Debt

Current Ratio8.25
Quick Ratio8.25

Price-To-Earnings

Sales & Book Value

Annual Sales$900,000.00
Price / Sales92.41
Price / Cash FlowN/A
Price / BookN/A

Profitability

Net Income$-65,980,000.00
Net Margins-8,513.18%
Return on Assets-61.20%

Miscellaneous

Employees62
Market Cap$83.18 million
OptionableOptionable

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?

Idera Pharmaceuticals shares reverse split on the morning of Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals Inc (NASDAQ:IDRA) posted its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.15. The biotechnology company earned $0.15 million during the quarter, compared to the consensus estimate of $2.09 million. Idera Pharmaceuticals had a negative return on equity of 69.28% and a negative net margin of 8,513.18%. View Idera Pharmaceuticals' Earnings History.

When is Idera Pharmaceuticals' next earnings date?

Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Idera Pharmaceuticals.

What price target have analysts set for IDRA?

6 Wall Street analysts have issued 1 year price targets for Idera Pharmaceuticals' stock. Their forecasts range from $14.00 to $32.00. On average, they expect Idera Pharmaceuticals' stock price to reach $22.50 in the next year. This suggests a possible upside of 635.3% from the stock's current price. View Analyst Price Targets for Idera Pharmaceuticals.

What is the consensus analysts' recommendation for Idera Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Idera Pharmaceuticals.

What are Wall Street analysts saying about Idera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (1/16/2019)
  • 2. HC Wainwright analysts commented, "We are maintaining our Buy rating of IDRA shares and our 12-month price target of $18.00 per share. We derive our price target based on a risk-adjusted net present value analysis of projected tilsotolimod revenues through 2027 assuming a 12% discount rate and 3% terminal growth rate. We derive an rNPV of $1.07B for tilsotolimod and upon inclusion of $94M in cash and cash equivalents to arrive at a 12-month price target of $17.73 per diluted share, which we round to $18.00." (10/22/2018)

Has Idera Pharmaceuticals been receiving favorable news coverage?

News headlines about IDRA stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Idera Pharmaceuticals earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are some of Idera Pharmaceuticals' key competitors?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 55)
  • Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 50)
  • Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 56)
  • Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Sudhir Agrawal D.Phil., F.R.S.C., Scientific Advisor (Age 65)

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.04%). Company insiders that own Idera Pharmaceuticals stock include Bros Advisors Lp Baker, Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Bryant David Lim, Carol Schafer, James A Geraghty, Joanna Horobin and Vincent Milano. View Insider Buying and Selling for Idera Pharmaceuticals.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $3.06.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $83.18 million and generates $900,000.00 in revenue each year. The biotechnology company earns $-65,980,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. Idera Pharmaceuticals employs 62 workers across the globe.

What is Idera Pharmaceuticals' official website?

The official website for Idera Pharmaceuticals is http://www.iderapharma.com.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]


MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel